Abstract:BACKGROUND:Aberrant expression of the RON receptor tyrosine kinase is a pathogenic feature and a validated drug target in various types of cancers. Currently, therapeutic antibodies targeting RON for cancer therapy are under intensive evaluation. Here we report the development and validation of a novel humanized anti-RON antibody-drug conjugate for cancer therapy.METHODS:Antibody humanization was achieved by grafting sequences of complementarity-determining regions from mouse monoclonal antibody Zt/g4 into human IgG1/κ acceptor frameworks. The selected humanized Zt/g4 subclone H1L3 was conjugated with monomethyl auristatin E using a dipeptide linker to form H-Zt/g4-MMAE. Pharmacokinetic analysis of H-Zt/g4-MMAE was determined using hydrophobic interaction chromatography and a MMAE ADC ELISA kit. Biochemical and biological assays were used for measuring RON expression, internalization, cell viability and death. Therapeutic efficacies of H-Zt/g4-MMAE were validated in vivo using three pancreatic cancer xenograft models. Toxicological activities of H-Zt/g4-MMAE were determined in mouse and cynomolgus monkey.RESULTS:H-Zt/g4-MMAE had a drug to antibody ratio of 3.77:1 and was highly stable in human plasma with a dissociation rate less than 5% within a 20 day period. H-Zt/g4-MMAE displayed a favorable pharmacokinetic profile in both mouse and cynomolgus monkey. In vitro, H-Zt/g4-MMAE induced RON internalization, which results in killing of pancreatic cancer cells with IC50 values at 10-20 nM. In vivo, H-Zt/g4-MMAE inhibited pancreatic cancer xenograft growth with tumoristatic concentrations at 1~3 mg/kg bodyweight. Significantly, H-Zt/g4-MMAE eradicated tumors across multiple xenograft models regardless their chemoresistant and metastatic statuses. Moreover, H-Zt/g4-MMAE inhibited and eradicated xenografts mediated by pancreatic cancer stem-like cells and by primary cells from patient-derived tumors. Toxicologically, H-Zt/g4-MMAE is well tolerated in mice up to 60 mg/kg. In cynomolgus monkey, H-Zt/g4-MMAE up to 30 mg/kg had a manageable and reversible toxicity profile.CONCLUSIONS:H-Zt/g4-MMAE is superior in eradication of pancreatic cancer xenografts with favorable pharmacokinetic profiles and manageable toxicological activities. These findings warrant the transition of H-Zt/g4-MMAE into clinical trials in the future.

Characterization of a Novel Anti-DR5 Monoclonal Antibody WD1 with the Potential to Induce Tumor Cell Apoptosis

A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity in Vitro and in Vivo

The Characteristic of an Anti-Human DR5 Antibody A6

Tumor-cell Specific Cytotoxic Activity of LBY135, a Novel Anti- DR5 Agonistic Antibody

The Construction and Expression of A Novel Chimeric Anti-Dr5 Antibody

Structural Basis of LaDR5, a Novel Agonistic Anti-Death Receptor 5 (DR5) Monoclonal Antibody, to Inhibit DR5/TRAIL Complex Formation

The tetravalent anti-DR5 antibody without cross-linking direct induces apoptosis of cancer cells.

Analysis of aDR5scFv with Specific Identification and Function.

Preparation and Characterization of A Set of Monoclonal Antibodies to Trail and Trail Receptors Dr4, Dr5, Dcr1, and Dcr2

Preparation, Characterization, and Activity Analysis of Monoclonal Antibodies Against Human Death Receotor 5

[Construction and expression of anti-tumor necrosis factor related apoptosis-inducing ligand receptor death receptor 5 chimeric antibody in eukaryotic cells]

Induction of Apoptosis in U343 Cell Line by a Novel Anti-Human DR5 Monoclonal Antibody

The Preparation and Tumor Cell Apoptosis-Inducing Activity Assay of Anti-Human DR5 Single-Chain Antibody

Small-molecule Activation of the TRAIL Receptor DR5 in Human Cancer Cells

Analysis of Trail Receptor Expression Using Anti-Trail Death Receptor-5 Monoclonal Antibodies

Antitumor Efficacy of LBY135, an Anti-Dr5 Monoclonal Antibody, Alone or in Combination with Chemotherapy in Human Colon Tumor Cell Lines and Xenografts

The Antitumor Activity Of Tcr-Mimic Antibody-Drug Conjugates (Tcrm-Adcs) Targeting The Intracellular Wilms Tumor 1 (Wt1) Oncoprotein

Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Combination of multivalent DR5 receptor clustering agonists and histone deacetylase inhibitors for treatment of colon cancer

Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy

Expression and Preparation of Recombinant Human Soluble DR5 and Detection of Its Biological Activity